COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease
Modern Rheumatology, doi:10.1093/mr/roac074
Objectives: To evaluate the impact of familial Mediterranean fever (FMF) features on the clinical course and outcomes of coronavirus disease 2019 (COVID-19) and clinical course of FMF after COVID-19. Methods: Consecutive FMF patients with COVID-19 were enrolled from three referral hospitals. Clinical features of FMF and detailed COVID-19 information were obtained from patient interviews and medical records. Results: Seventy-three FMF patients were included in the study. 94.5% of patients had clinical symptoms of COVID-19. We found 24.7% hospitalization, 12.3% respiratory support, 4.1% intensive care unit admission, 6.8% complication, and 1.4% mortality rate in patients. The risk factors of hospitalization for respiratory support were male gender [OR: 7.167 (95% CI: 1.368-37.535)], greater age [OR: 1.067 (95% CI: 1.016-1.121)], and non-adherence to colchicine treatment before the infection [OR: 7.5 (95% CI: 1.348-41.722)]. One-third of patients had reported attacks after COVID-19. The patterns of triggered attacks were fever, peritonitis, pleuritis, transient arthritis, chronic knee mono-arthritis, and protracted febrile myalgia. Conclusions: FMF characteristics were not associated with worse outcomes of COVID-19. Colchicine non-adherence was the risk factor of hospitalization for oxygen support. The rate of FMF attacks after COVID-19 is prominently increased, with some of them being protracted and destructive.
Conflict of interest None declared.
Ethics approval and consent to participate and for publication This study was approved by the Ministry of Health and Gazi University Hospital Ethics Committee (protocol number: 322, 29/03/2021) and followed the guidelines from Helsinki Declaration. All patients signed the informed consent, including consent for publication.
Bourguiba, Delplanque, Vinit, Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218707
Gao, Ding, Dong, Risk factors for severe and critically ill COVID-19 patients: a review, Allergy, doi:10.1111/all.14657
Güven, Erden, Karaka S Ö, COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study, Rheumatol Int, doi:10.1007/s00296-021-04812-8
Henderson, Canna, Schulert, On the alert for cytokine storm: immunopathology in COVID-19, Arthritis Rheumatol, doi:10.1002/art.41285
Issa, Merhi, Panossian, SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis, mSystems, doi:10.1128/mSystems.00266-20
Kharouf, Ishay, Kenig, Incidence and course of COVID-19 hospitalisations among patients with familial Mediterranean fever, Rheumatology, doi:10.1093/rheumatology/keab577
Kow, Lee, Ramachandram, The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: a meta-analysis of randomised trials, Immun Inflamm Dis, doi:10.1002/iid3.562
Kukuy, Beckerman, Dinour, Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever, Rheumatology, doi:10.1093/rheumatology/keaa772
Qin, Zhou, Hu, Dysregulation of Immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin Infect Dis, doi:10.1093/cid/ciaa248
Strangfeld, Sch Ä Fer, Gianfrancesco, Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219498
Tufan, Lachmann, Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review, Turk J Med Sci, doi:10.3906/sag-2008-11
Tufan, Matucci-Cerinic, Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation, Turk J Med Sci, doi:10.3906/sag-2110-179
Wang, Hu, Hu, Clinical characteristics of 138 hospitalised patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Yang, Shen, Li, Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, J Allergy Clin Immunol, doi:10.1016/j.jaci.2020.04.027
Özen, Sag, Ben-Chetrit, Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach, Rheumatology, doi:10.1093/rheumatology/keaa863